Latest News

FDA Approves Ivosidenib for IDH1-Mutated Relapsed/Refractory Acute Myeloid Leukemia

FDA Approves Ivosidenib for IDH1-Mutated Relapsed/Refractory Acute Myeloid Leukemia

Ivosidenib is the first-in-class FDA approval for IDH1 mutation-harboring acute myeloid leukemia.

Clinical Stage at First Response May Predict Outcomes in Chronic Lymphocytic Leukemia

Clinical Stage at First Response May Predict Outcomes in Chronic Lymphocytic Leukemia

Clinical stage determined by the Binet staging system could be an accurate response surrogate among patients with chronic lymphocytic leukemia.

Increased Body Mass Index May Be Predictive of Recurrence, Progression in Bladder Cancer

Increased Body Mass Index May Be Predictive of Recurrence, Progression in Bladder Cancer

Evidence for the impact of obesity on outcomes for bladder cancer have been conflicting and require further study.

Aspirin, Non-Aspirin NSAID-Use May Improve Survival Outcomes in Ovarian Cancer

Aspirin, Non-Aspirin NSAID-Use May Improve Survival Outcomes in Ovarian Cancer

Previous studies have suggested that analgesic medicine use may have a protective effect for patients with ovarian cancer.

Ribociclib FDA-Approved For Additional Indications in HR+, HER2- Advanced Breast Cancer

Ribociclib FDA-Approved For Additional Indications in HR+, HER2- Advanced Breast Cancer

The FDA based its approval on the results of a triplet of phase 3 studies, the MONALEESA-2, MONALEESA-3, and MONALEESA-7.

First-Line Atezolizumab Plus Bevacizumab Receives Breakthrough Therapy Designation for HCC

First-Line Atezolizumab Plus Bevacizumab Receives Breakthrough Therapy Designation for HCC

Twenty-three systemic therapy-naive patients with advanced hepatocellular carcinoma received atezolizumab plus bevacizumab every 3 weeks.

Drugs Approved Under the Breakthrough Therapy Pathway Lack Basic Features of High-Quality Trials

Drugs Approved Under the Breakthrough Therapy Pathway Lack Basic Features of High-Quality Trials

Close postmarketing monitoring will be especially crucial for drugs approved with a breakthrough therapy designation, as many of them were given a pass on the basis of a single pivotal trial.

Combined Modality Therapy May Be More Effective Than Radiotherapy Alone in Follicular Lymphoma

Combined Modality Therapy May Be More Effective Than Radiotherapy Alone in Follicular Lymphoma

Evidence from previous studies have demonstrated that combined modality therapy with chemotherapy and radiotherapy may improve long-term outcomes in this patient population.

Chemotherapy May Improve Survival Outcomes in High-Risk Soft-Tissue Sarcoma

Chemotherapy May Improve Survival Outcomes in High-Risk Soft-Tissue Sarcoma

A study investigating the effects of adjuvant chemotherapy showed that treatment improved metastases-free survival and overall survival among patients with soft-tissue sarcoma and high-risk factors.

CRISPR Method of Gene Editing Creates Massive Genetic Reshuffling

CRISPR Method of Gene Editing Creates Massive Genetic Reshuffling

Drug developers relying on CRISPR-Cas9 platforms for the creation of gene therapies saw their shares slide when it was revealed that the technique may inadvertently cause disruptions of larger chunks of DNA than previously thought.

3 Social Media Do's and Don'ts for Oncologists

3 Social Media Do's and Don'ts for Oncologists

Social media has become a popular networking and marketing platform for oncologists. Here's what to do and what not to do on social media.

Pazopanib Plus Cetuximab May Be Effective and Well-Tolerated in Head and Neck Cancer

Pazopanib Plus Cetuximab May Be Effective and Well-Tolerated in Head and Neck Cancer

Only a few studies have investigated the effectiveness of pazopanib and cetuximab, an angiogenesis inhibitor and EGFR inhibitor, respectively, for head and neck squamous cell carcinoma.

FDA Approves Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer

FDA Approves Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer

This latest approval now makes enzalutamide the only FDA-approved oral medication indicated for both metastatic and nonmetastatic castration-resistant prostate cancer.

Aggressive Follow-Up Imaging in Breast Cancer Is Geography-Specific

Aggressive Follow-Up Imaging in Breast Cancer Is Geography-Specific

Variations in the use and frequency of advanced imaging post-surgery in patients with breast cancer were observed across regions of the United States.

Pembrolizumab May Lead to Favorable Long-Term Outcomes in Head and Neck Cancer

Pembrolizumab May Lead to Favorable Long-Term Outcomes in Head and Neck Cancer

The anti-programmed death 1 (PD-1) antibody pembrolizumab was determined to be an effective second-line option for patients with head and neck cancers.

Biomarker-Based Blood Test May Extend Reach of CT Screening for Certain Lung Cancers

Biomarker-Based Blood Test May Extend Reach of CT Screening for Certain Lung Cancers

Although they fall outside official testing guidelines for lung cancer, people who have smoked at all in their lifetime could still be at risk for the disease. Researchers propose a biomarker test for 4 proteins could identify more individuals that could benefit from subsequent screening.

Tucatinib May Be A Safe, Novel Treatment for ERBB2/HER2-Positive Breast Cancer

Tucatinib May Be A Safe, Novel Treatment for ERBB2/HER2-Positive Breast Cancer

For this phase 1b study, researchers enrolled 57 patients with ERBB2/HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.

Adding Ovarian Suppression May Improve Survival Outcomes in Premenopausal Breast Cancer

Adding Ovarian Suppression May Improve Survival Outcomes in Premenopausal Breast Cancer

Updated results of the SOFT and TEXT trial suggest that adding ovarian suppression to exemestane or tamoxifen could improve survival outcomes.

FDA Approves Nivolumab Plus Ipilimumab for MSI-H/dMMR Metastatic Colorectal Cancer

FDA Approves Nivolumab Plus Ipilimumab for MSI-H/dMMR Metastatic Colorectal Cancer

The FDA based its approval on evidence from the ongoing, non-randomized CheckMate-142 phase 2 study, for which researchers treated 119 patients with nivolumab plus ipilimumab.

Reprogramming T Cells Without Using Viral Vectors

Reprogramming T Cells Without Using Viral Vectors

According to recent research, scientists may not need to rely on the use of viral vectors to edit the genes of primary immune cells when creating cell and gene therapies.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs